|
Volumn 86, Issue 1, 1992, Pages 100-110
|
Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: A multicenter, randomized, double-blind placebo-controlled trial
w,aa,ac t f z g e w,aa,ac a,aa a a a a b b c c c d d d more..
i
OLV HOSPITAL
(Belgium)
|
Author keywords
angiotensin converting enzyme; cilazapril; clinical trials; percutaneous transluminal coronary angioplasty
|
Indexed keywords
ACETYLSALICYLIC ACID;
CILAZAPRIL;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
ADULT;
AGED;
ANGINA PECTORIS;
ANGIOCARDIOGRAPHY;
ARTICLE;
CLINICAL TRIAL;
CONTROLLED STUDY;
CORONARY ARTERY;
CORONARY ARTERY OBSTRUCTION;
COUGHING;
DISEASE COURSE;
DOSE TIME EFFECT RELATION;
DRUG EFFECT;
DRUG MECHANISM;
HEART INFARCTION;
HEART MUSCLE REVASCULARIZATION;
HUMAN;
HYPOTENSION;
MAJOR CLINICAL STUDY;
MORTALITY;
ORAL DRUG ADMINISTRATION;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
PROGNOSIS;
RANDOMIZED CONTROLLED TRIAL;
TRANSLUMINAL CORONARY ANGIOPLASTY;
|
EID: 0026766194
PISSN: 00097322
EISSN: None
Source Type: Journal
DOI: 10.1161/01.CIR.86.1.100 Document Type: Article |
Times cited : (476)
|
References (0)
|